|
|
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
| Bank Loan Ratings | 10.00 | ACUITE B+ | Reaffirmed & Withdrawn | - |
| Total Outstanding Quantum (Rs. Cr) | 0.00 | - | - |
| Total Withdrawn Quantum (Rs. Cr) | 10.00 | - | - |
| Rating Rationale |
|
Acuité has reaffirmed and withdrawn the long-term rating of 'ACUITE B+' (read as ACUITE B plus) on the Rs.10.00 crore bank facilities of Jambuwala Pharmaceuticals Limited (JPL). The rating withdrawal is in accordance with Acuité's policy on withdrawal of rating.
The rating is being withdrawn on account of request received from the company and NOC received from the banker. |
| About the Company |
|
JPL incorporated in the year 2017, is an Ahmedabad based company which is engaged in manufacturing and trading of generic medicines for human consumption. The company has set up a fully automated facility for production of capsules and tablets. The company was set up by Mr. Pranlal Bhailal Shah and Mr. Hiren Vijaykumar Doshi. The manufacturing facility is located in Sanand, Ahmedabad with an annual installed capacity of 6000 lakhs of tablets and 1500 lakhs of capsules respectively.
|
| Analytical Approach |
|
Acuité has considered the standalone business and financial risk profile of JPL to arrive at the rating.
|
Key Rating Drivers
| Strengths |
| Experienced management
JPL is promoted by Mr. Kamal Pranlal Shah, who possess more than a decade of experience in various field and is responsible for the overall financial and administrative operations of the company. He is supported by the other directors, Mr. Pranlal Bhailal Shah and Mr. Chintan Pranlal Shah who possess more than five decades and more than a decade of experience in the administration and accounts in the group companies. Apart from this, Mr. Hiren Vijaykumar Doshi, who heads the production division of the company has more than three decades of experience in the pharmaceutical industry and has been associated with reputed pharmaceutical companies. Acuité believes that the expertise of the management across various field is expected to benefit the company. Reputed clientele JPL has established relationship with various reputed pharmaceutical companies like IPCA Laboratories Limited, Antila Lifescience Private Limited, HBC Lifescience Private Limited amongst others which provides the required raw materials and quality control expertise for supervision to the company for carrying out the job-work activities. |
| Weaknesses |
| Below average financial risk profile
Financial risk profile of JPL is below average marked by low networth, moderate gearing and low debt protection metrics. The networth of the company has declined to Rs.3 Cr as on 31 March, 2022 as against Rs.5 Cr as on 31 March, 2021 on account of accumulated losses. The gearing (debt-equity) has marginally increased to 2.60 times as on 31 March, 2022 as against 2.15 times as on 31 March, 2021 on account of decline in the networth. The gearing of the company is further expected to increase on account of low networth and increase in the debt profile considering the requirement of availing the unutilised short-term working capital limit in the near to medium term. The total debt of Rs.9 Cr as on 31 March, 2022 consists of long term bank borrowings of Rs.5 Cr and unsecured loans from directors of Rs.4 Cr. The interest coverage ratio and DSCR both stood lower at same level of 1.41 times for FY2022 as against 2.01 times for FY2021 on account of absence of any current maturities of the existing long-term debt. The Net Cash Accruals to Total debt stood lower at 0.02 times for FY2022 as against 0.04 times for FY2021. The Total outside liabilities to Tangible net worth stood high at 3.18 times for FY2022 as against 2.30 times for FY2021. Acuité believes that ability of JPL to improve its financial risk profile in the near to medium term will remain a key monitorable. Nascent stage and modest scale of operations JPL reported modest revenue of Rs.2.57 Cr for FY2022 as against Rs.2.59 Cr in FY2021 considering the company being at its nascent stage of operations, since it got incorporated in the year 2017 and the commercial operations commenced from June 2020 onwards. Despite an overall increase in the manufacturing and job-work activities during FY2022 as against FY2021, the company still generated lowest revenue at a similar level due to its slowdown in the trading and commission-based activities during the same period. The operating margin of the company has further reduced to 26.15 percent in FY2022 as against 30.92 percent in FY2021 on account of its modest operating performance as well as the losses have also increased further during the year due to an increase in the depreciation and interest cost. For the current year FY2023, the company has achieved lowest sales of around Rs.1.14 Cr as on August 2022. Acuité believes that JPL's ability to increase its scale of operations and profitability in near to medium term will remain a key rating sensitivity factor. Working capital intensive operations The operations of JPL are highly working capital intensive marked by its Gross Current Assets (GCA) of 290 days for FY2022 as against 454 days for FY2021. This is primarily on account of high inventory days which stood at 127 days in FY2022 as against 10 days in FY2021. Inventory cycle of the company has increased on account of overall increase in the purchase of raw materials required for producing the various tablets and capsules and due to which the creditors cycle has increased to 303 days in FY2022 as against 27 days in FY2021. On the other hand, debtors cycle of the company has improved and stood at 110 days in FY2022 as against 665 days in FY2021. Acuité believes that any further deterioration in the working capital cycle will remain a key monitorable. |
| Rating Sensitivities |
|
| Material covenants |
| None |
| Liquidity position - Stretched |
|
JPL has stretched liquidity position marked by low net cash accruals (NCA) against no maturing debt obligations. The company generated cash accruals in the range of Rs.0.03 Cr to Rs.0.20 Cr during FY2020 to FY2022 against no repayment obligation during the same period. Going forward the NCA are expected of ~Rs.1 Cr for period FY2023-FY2024 against repayment obligation of ~Rs.2 Cr for the same period. The working capital operations of the company are highly intensive marked by its gross current asset (GCA) days of 290 days for FY2022 as against 454 days for FY2021 on account of high inventory days during the same period. The short-term working capital limit from the bank however remained unutilised during FY2022 as the company is meeting its working capital requirements through its receipts from trading and job work income as well as unsecured loans from promoters. Current ratio stands at 1.08 times as on 31 March 2022.
Acuité believes that the liquidity of JPL is likely to remain stretched over the medium term on account of generating low net cash accruals against its debt obligations. |
| Outlook |
| Not applicable |
| Other Factors affecting Rating |
| None |
| Particulars | Unit | FY 22 (Actual) | FY 21 (Actual) |
| Operating Income | Rs. Cr. | 2.57 | 2.59 |
| PAT | Rs. Cr. | (1.51) | (1.06) |
| PAT Margin | (%) | (58.94) | (40.86) |
| Total Debt/Tangible Net Worth | Times | 2.60 | 2.15 |
| PBDIT/Interest | Times | 1.41 | 2.01 |
| Status of non-cooperation with previous CRA (if applicable) |
| None |
| Any other information |
| None |
| Applicable Criteria |
|
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
| Note on complexity levels of the rated instrument |
| https://www.acuite.in/view-rating-criteria-55.htm |
|
| |
|
|
||||||||||||||||||||||||||||||||
|
|
Contacts |
| Analytical | Rating Desk |
| About Acuité Ratings & Research |
